Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 9:22 PM
Ignite Modification Date: 2025-12-25 @ 7:09 PM
NCT ID: NCT06212804
Description: The safety analysis set included all participants who received trial intervention (active or placebo).
Frequency Threshold: 0
Time Frame: From study intervention administration (Day 1) up to end of follow-up (Day 71)
Study: NCT06212804
Study Brief: A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Cohort 1: VIS954 Dose 1 Participants received a single dose of VIS954 at Dose 1 via SC injection on Day 1. 0 None 0 7 2 7 View
Cohort 2: VIS954 Dose 2 Participants received a single dose of VIS954 at Dose 2 via SC injection on Day 1. 0 None 0 7 1 7 View
Cohort 3: VIS954 Dose 3 Participants received a single dose of VIS954 at Dose 3 via SC injection on Day 1. 0 None 0 7 1 7 View
Cohort 4: VIS954 Dose 4 Participants received a single dose of VIS954 at Dose 4 via SC injection on Day 1. 0 None 0 7 1 7 View
Cohort 5: VIS954 Dose 5 Participants received a single dose of VIS954 at Dose 5 via SC injection on Day 1. 0 None 0 7 3 7 View
Cohort 6: VIS954 Dose 6 Participants received a single dose of VIS954 at Dose 6 via SC injection on Day 1. 0 None 0 7 2 7 View
Cohort 1 to 6: Pooled Placebo Participants received a single dose of placebo matched to VIS954 via SC injection on Day 1. 0 None 0 12 4 12 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Blood loss anaemia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (27.0) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (27.0) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (27.0) View
Injection site bruising SYSTEMATIC_ASSESSMENT General disorders MedDRA (27.0) View
Injection site pruritus SYSTEMATIC_ASSESSMENT General disorders MedDRA (27.0) View
Injection site reaction SYSTEMATIC_ASSESSMENT General disorders MedDRA (27.0) View
Upper respiratory tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (27.0) View
Arthralgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (27.0) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (27.0) View
Rhinorrhoea SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (27.0) View